{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NUZ.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NUZ.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","market":"AU","secType":"STK","nameCN":"NEURIZON THERAPEUTICS LTD","latestPrice":0.11,"timestamp":1745302320000,"preClose":0.12,"halted":0,"volume":26517,"delay":0,"nameEN":"NEURIZON THERAPEUTICS LTD","floatShares":351374969,"shares":492305766,"eps":-0.033278,"marketStatus":"Not Yet Opened","change":-0.01,"latestTime":"04-22 16:12:00 AEST","open":0.12,"high":0.12,"low":0.11,"amount":2948,"amplitude":0.083333,"askPrice":0.12,"askSize":166133,"bidPrice":0.115,"bidSize":21000,"shortable":3,"etf":0,"ttmEps":-0.033278,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.12,"openAndCloseTimeList":[[1745280000000,1745301600000]],"volumeRatio":0.16370681049105815,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","floatShares":351374969,"roa":"-60.46%","roe":"-150.50%","lyrEps":-0.020692,"volumeRatio":0.16370681049105815,"shares":492305766,"dividePrice":0,"high":0.12,"amplitude":0.083333,"preClose":0.12,"low":0.11,"week52Low":0.096,"pbRate":"4.55","psRate":"35.73","week52High":0.26,"institutionHeld":0,"latestPrice":0.11,"committee":-0.775561,"eps":-0.033278,"divideRate":0,"volume":26517,"delay":0,"ttmEps":-0.033278,"open":0.12,"prevYearClose":0.17,"prevWeekClose":0.12,"prevMonthClose":0.13,"prevQuarterClose":0.13,"fiveDayClose":0.105,"twentyDayClose":0.11,"sixtyDayClose":0.135},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NUZ.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2482975220","title":"Neurizon Therapeutics Receives Positive Opinion on Orphan Medicinal Product Designation for Nuz-001 in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2482975220","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482975220?lang=en_us&edition=fundamental","pubTime":"2024-11-11 15:09","pubTimestamp":1731308995,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nFWN3MF2XB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"gpt_icon":0},{"id":"2482216424","title":"Neurizon’s fast-track application for flagship drug in Europe received ‘positively’","url":"https://stock-news.laohu8.com/highlight/detail?id=2482216424","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482216424?lang=en_us&edition=fundamental","pubTime":"2024-11-11 07:54","pubTimestamp":1731282840,"startTime":"0","endTime":"0","summary":"While the final decision is set for next month, biotech player Neurizon’s  hopes have been lifted with a view towards winning fast-track status from a European health regulator.The European Medicines Agency  – “a decentralised agency of the European Union responsible for … safety monitoring,” according to its website – has delivered to Neurizon “notice of a positive opinion”。That opinion relates to Neurizon’s bid to acquire Orphan Medicinal Product Designation  from EMA for its drug NUZ-001, designed in the hopes it can treat Amyotrophic Lateral Sclerosis .According to Hopkins Medicine, ALS is a fatal motor neurone disease that causes nerve cells in the spine and brain to dysfunction. The condition has no cure.The EU, Neurizon also stated on Monday, has double the ALS patients that the USA has –making that region its target market.As for its OMPD application, that would effectively have EMA officially register NUZ-001 as a promising research drug of interest, which naturally implies a ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/neurizons-fast-track-application-for-flagship-drug-in-europe-received-positively-2024-11-11/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7096","NUZ.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":42,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NUZ.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NUZ.AU\",market:\"AU\",,,undefined,":[]}}